How do antifungals behave in septic shock? small study aims to find out

NCT ID NCT02805049

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 4 study looked at how the body processes echinocandin antifungal drugs (caspofungin or micafungin) in 24 adults with septic shock caused by peritonitis. Researchers measured drug levels in the blood to understand clearance, distribution, and concentration. The goal was to gather knowledge for better dosing, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Echinocandins (caspofungin or micafungin)
What this could lead to: If successful, this could help doctors better dose echinocandins for septic shock patients with abdominal infections, potentially improving treatment outcomes.
What could go wrong: This is a small, completed pharmacokinetic study with only 24 participants, so results may not apply broadly. It does not test whether the drugs improve survival or cure the infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERITONITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peritonitis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERITONITIS SEPTIC SHOCK

Contacts and locations

Locations

CHU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, 30029, France
Royal Brisbane Women's Hospital

Herston, 4029, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.